Tilray’s Aphria RX GmbH Subsidiary Completes First Successful Harvest and Delivery of Medical Cannabis Grown in Germany
July 07 2021 - 8:10AM
Business Wire
Milestone GMP-Certified Medical Cannabis
Distributed to German Pharmacies
Tilray, Inc. (NASDAQ | TSX: TLRY), a global pioneer in cannabis
research, cultivation, production, and distribution, today
announced that its wholly-owned subsidiary in Germany, Aphria RX
GmbH, has completed the first successful harvest of medical
cannabis cultivated in Germany for distribution to German
pharmacies. The medical cannabis harvest is the first cultivated
under European Good Manufacturing Practices (EU GMP) standard at
Tilray’s state-of-the-art 6,000 square meter indoor growing
facility in Neumünster, Germany. The subsequent distribution, which
was carried out by a distributor on behalf of the German Cannabis
Agency and in accordance with all pharmaceutical and narcotic legal
requirements, underscores Tilray’s strong foothold and operational
excellence within Europe’s key medical cannabis market.
“Our harvest in Germany represents an important milestone in
granting access to high-quality and trustworthy medical cannabis to
patients and healthcare professionals in Germany,” said Denise
Faltischek, Tilray's Head of International and Chief Strategy
Officer. “It is a testament to the professionalism and dedication
of our team that, despite the challenges of a global pandemic, we
remained on track as the first licensed producer to cultivate
medical cannabis in Germany. Our achievement would not have been
possible without the trust and cooperation of the Federal Institute
for Drugs and Medical Devices (BfArM) and the Germany Cannabis
Agency, for which we are sincerely grateful.”
Since Germany’s Cannabis as Medicines Act was enacted in March
2017, the country has relied exclusively on imports to meet the
growing medical demand currently estimated at well over 100,000
patients. Tilray’s ongoing domestic harvest and production will
play an indispensable role in ensuring that patient needs are met
with products of the highest quality medical cannabis while at the
same time reducing dependence on imported supply.
Irwin D. Simon, Tilray’s Chief Executive Officer, added, “The
European Union represents a powerful growth market for us and,
among its constituent markets, Germany possesses the greatest
potential. We look forward to leveraging our strong medical
platform and our multifaceted international operation, which
combines in-country cultivation, importation, and large
distribution infrastructure, to increase access and availability to
high-quality, consistent medical cannabis for all European
patients.”
Mr. Simon concluded, “Tilray’s achievement in Germany serves as
a strong affirmation that we are competitively differentiated by
scale and proven execution skills. As a result, we are poised to
transform the industry globally with our highly scalable footprint,
portfolio of diverse medical cannabis brands, and compelling
products that respond to a wide range of patient and consumer
needs. The E.U. is central to our worldwide distribution network,
and we look forward to accelerating our progress.”
Tilray has a pioneering track record as a company committed to
making GMP-certified, pharmaceutical-grade medical cannabis
products available to patients in need worldwide and was the first
to successfully export medical cannabis from Canada and import
medical cannabis products into the E.U. in 2016.
About Tilray
Tilray Inc. is a leading global cannabis-lifestyle and consumer
packaged goods company with operations in Canada, the United
States, Europe, Australia, and Latin America that is changing
people’s lives for the better – one person at a time – by inspiring
and empowering the worldwide community to live their very best life
by providing them with products that meet the needs of their mind,
body, and soul and invoke a sense of wellbeing. Tilray’s mission is
to be the trusted partner for its patients and consumers by
providing them with a cultivated experience and health and
wellbeing through high-quality, differentiated brands and
innovative products. A pioneer in cannabis research, cultivation,
and distribution, Tilray’s unprecedented production platform
supports over 20 brands in over 20 countries, including
comprehensive cannabis offerings, hemp-based foods, and alcoholic
beverages.
Forward-Looking Statements
Certain statements in this communication that are not historical
facts constitute forward-looking information or forward-looking
statements (together, “forward-looking statements”) under Canadian
securities laws and within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that are intended to
be subject to the “safe harbor” created by those sections and other
applicable laws. Forward-looking statements can be identified by
words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication. Many
factors could cause actual results, performance or achievement to
be materially different from any forward-looking statements, and
other risks and uncertainties not presently known to the Company or
that the Company deems immaterial could also cause actual results
or events to differ materially from those expressed in the
forward-looking statements contained herein. For a more detailed
discussion of these risks and other factors, see the most recently
filed annual information form of Aphria and the Annual Report on
Form 10-K (and other periodic reports filed with the SEC) of Tilray
made with applicable securities regulatory authorities and
available on SEDAR and EDGAR. The forward-looking statements
included in this communication are made as of the date of this
communication and the Company does not undertake any obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210707005512/en/
For media inquiries, please contact: Berrin Noorata
news@tilray.com
For investor inquiries please contact: Raphael Gross
203-682-8253 Raphael.Gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Apr 2023 to Apr 2024